Categories LATEST, Other Industries

Celgene gets a booster shot from recent positive clinical trial results

Troubled pharma giant Celgene (CELG) has announced 3 positive clinical trial results in the past two weeks. Today, the company reported positive results for its Phase III study of a breast cancer treatment, which was sponsored by Roche. Celgene, along with Acceleron Pharma (XLRN), had reported positive results recently in other two clinical trials.

“The IMpassion130 results are extremely encouraging for patients with this highly aggressive form of breast cancer for which there are limited options,” said CMO Jay Backstrom.  According to the American Cancer Society, it is projected that 266,120 women in the US will be diagnosed with invasive breast cancer and 40,920 women will die because of it in 2018.

Related: Celgene plunges to a new 52-week low

On Monday, Celgene and Acceleron reported that blood-disorder drug Luspatercept met the endpoints of Phase III study. On June 28, both the companies announced that Luspatercept met the endpoints in the treatment of beta-thalassaemia study. The companies plan to apply for regulatory approvals for Luspatercept in the US and Europe during the first six months of 2019.

Celgene will be discussing the data from all these three clinical trials in the upcoming medical meetings in this year.

Celgene stock rose 2% in the pre-market trading session and continued to trade in the positive territory when the market opened today. Shares of Celgene, which hit its yearly low on May 21, were trading between $74.13 and $147.17 in the past one year and plunged about 20% so far this year.

Related: Celgene inks a deal with Skyhawk Therapeutics

Meanwhile, Acceleron stock was up 3% today. It’s worth noting that shares of Acceleron have skyrocketed 44% and Celgene shares climbed 10% after their announcement on June 28.

Most Popular

Salesforce stock hit by weak guidance, co-CEO’s exit. What next?

For technology stocks, 2022 has been a challenging year, with companies losing significant market value amid prolonged stock selloff. In that respect, Salesforce, Inc. (NYSE: CRM) is among the worst-affected

Macy’s (M): Here’s a look at the retailer’s expectations for the near term

Shares of Macy’s Inc. (NYSE: M) were down on Thursday. The stock has gained 36% over the past three months and 18% over the past one month. The company’s sales

KR Earnings: Kroger Q3 sales, profit increase and top expectations

Department store chain The Kroger Co. (NYSE: KR) on Thursday said its third-quarter sales and adjusted earnings increased year-over-year. The latest numbers also exceeded the market's expectations. Net earnings attributable to

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top